Hansa Biopharma confirms follow-up meeting with FDA
In line with previous guidance, Hansa Biopharma has scheduled a follow-up meeting with the U.S. Food and Drug Administration. The meeting will take place on November 20th, 2019.Lund, Sweden September 25, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced that a date for a follow- up meeting with the U.S. Food and Drug Administration (FDA) has now been confirmed. The meeting will take place on November 20th, 2019. At the upcoming meeting with the FDA, Hansa Biopharma intends to continue the discussion from December 2018